Injection site bullous eruption and generalized rash induced by pegylated interferon treatment for hepatitis C

Gastroenterology and Hepatology

Volumn 5, Issue 10, 2009, Pages 715-718

  Toney, Rachel C ^a   Agrawal, Rad M ^a   Loeffert, Martha ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CLOBETASOL; ESOMEPRAZOLE; HEMOGLOBIN; HYDROXYZINE; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; VENLAFAXINE;

ADULT; ALLERGIC URTICARIA; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; CHRONIC ACTIVE HEPATITIS; DEPRESSION; DRUG WITHDRAWAL; ERYTHEMA; FAMILY HISTORY; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; KOREA; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FUNCTION; OUTCOME ASSESSMENT; PREGNANCY DIABETES MELLITUS; PUNCH BIOPSY; RASH; RHEUMATOID ARTHRITIS; SKIN PRURITUS; THIGH; TREATMENT DURATION; TREATMENT OUTCOME; VESICULAR RASH; VIRUS LOAD;

EID: 72149120550     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, er al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
2. Schlesinger TE, Camisa C, Gay JD, Bergfeld WF. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol. 1997;36(6 pt 1):1023-1025.
3. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2007;19:817-820.
4. Midian-Singh R, Alagugurusamy S, Agrawal R. Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C. Gastroenterol Hepatol. 2007;3:644-647.
5. Guilabert A, Bosch X, Julià M, Iranzo P, Mascarò JM Jr. Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin. Br J Dermatol. 2005;152:377-379.
6. Conde-Taboada A, de la Torre C, Feal C, Mayo E, Gonzalez-Sixto B, Cruces MJ. Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection. Br J Dermatol. 2005;153:1070-1072.
7. Dohmen K, Miyamoto Y, Irie K, Takeshita T, Ishibashi H. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis C associated with primary biliary cirrhosis. J Gastroenterol. 2000;35:789-793.
8. Willems M, Munte K, Vrolijk JM, Den Hollander JC, Böhm M, et al. Hyper-pigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol. 2003;149:390-394.
9. Arrue I, Saiz A, Ortiz-Romero PL, Rodríguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34(suppl 1):18-21.
10. Tursen U, Kaya TI, Ikizoglu G. Interferon-alpha 2b induced facial erythema in a woman with chronic hepatitis C infection. J Eur Acad Dermatol Venereol. 2002;16:285-286.
11. Heinzerling L, Dummer R, Wildberger H, Burg G. Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient. Dermatology. 2000;201:154-157.
12. Basaranoglu M, Celebi S, Karaaslan H, Demir A. Case study on drug-related adverse effects of hepatitis C therapy. Adv Ther. 2006;23:769-771.
13. Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140:215-217.
14. Kawada K, Maeda N, Kobayashi S, Sowa J, Tsuruta D, Kawada N. Injection site with generalized rash caused by pegylated interferon alpha 2a injection. Dermatology. 2006;212:82-83.
15. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol. 2007;34:577-582.
16. Sookoian S, Neglia V, Castaño G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol. 1999;135:1000-10001.
17. Manjon-Haces JA, Vázquez-López F, Gómez-Díez S, Hidalgo-García A, Pérez-Alvarez R, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol. 2001;81:223-223
18. Dereurc O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142-1146. (Pubitemid 36963020)
19. Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol. 2004;84:120-123.
20. Montesu MA, Siddi V, Satta R, Pirodda C, Cottoni F. Bullous lesions at polyethylene glycol interfcron-alpha-2a inoculation site in a hepatitis C virus infected subject. Acta Derm Venereol. 2007;87:433-434.
21. Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology. 1993;186:155-157.